A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
← catalyst calendarNCT06539507 · readout ≤ 73 d
Sponsored by BioCryst Pharmaceuticals (industry) · BCRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
78estimated
Sites
12
Countries
Australia, France, Germany +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-26 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Netherton Syndrome
Interventions
- Drug: BCX17725
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs)
measured From screening through EOS (ie, through Day 78 in Parts 1 and 3, and Day 106 in Part 2)
Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12 (Part 4)
measured From baseline to Week 12
Permalink · BCRX's whole pipeline · Catalyst calendar · Every registered study · What changed